Table 1b.
Age-adjusted clinical characteristics of prostate cancer cases at the time of diagnosis, by race and European ancestry, Health Professionals Follow-up Study (n=7,088)
| African American | Asian American | European American | ||||
|---|---|---|---|---|---|---|
| All white | Southern European | Scandinavian | Other European | |||
|
| ||||||
| N | 89 | 90 | 6,909 | 1,677 | 777 | 4,455 |
| Year of diagnosis | ||||||
| 1986–1989, % | 4.2 | 3.4 | 4.9 | 4.5 | 5.5 | 4.9 |
| 1990–1994, % | 30.2 | 18.9 | 19.1 | 18.4 | 18.9 | 19.3 |
| 1995–1999, % | 20.0 | 20.2 | 21.7 | 21.8 | 22.0 | 21.6 |
| 2000–2004, % | 24.4 | 23.1 | 22.7 | 23.0 | 22.0 | 22.7 |
| 2005–2009, % | 13.8 | 20.6 | 19.7 | 19.2 | 19.1 | 19.9 |
| 2010–2014, % | 5.3 | 11.8 | 10.0 | 10.6 | 10.4 | 9.6 |
| 2015–2016, % | 2.2 | 2.0 | 2.0 | 2.4 | 2.1 | 1.9 |
| Mean age at diagnosis, years (SD)a | 70.3 (6.7) | 70.7 (7.0) | 70.1 (7.5) | 69.8 (7.5) | 69.2 (7.4) | 70.4 (7.4) |
| Mean PSA at diagnosis, ng/mL (SD) | 13.9 (17.7) | 26.3 (99.8) | 17.8 (152.3) | 15.3 (141.2) | 30.7 (269.0) | 16.5 (127.0) |
| Primary treatment | ||||||
| Radical prostatectomy, % | 32.9 | 29.6 | 38.1 | 37.8 | 41.0 | 37.8 |
| Radiation, % | 23.4 | 31.3 | 30.9 | 30.5 | 29.0 | 31.3 |
| Hormones, % | 5.3 | 8.8 | 6.8 | 6.1 | 7.0 | 7.1 |
| Active surveillance/no treatment, % | 14.9 | 10.5 | 9.3 | 10.1 | 8.2 | 9.2 |
| Other treatment, % | 1.0 | 0 | 1.9 | 1.8 | 1.9 | 1.8 |
| Unknown treatment, % | 22.4 | 19.9 | 13.0 | 13.7 | 12.9 | 12.7 |
| TNM Stageb | ||||||
| T1/T2, % | 86.9 | 80.0 | 82.9 | 84.4 | 81.2 | 82.7 |
| T3a, % | 1.3 | 8.5 | 8.1 | 7.7 | 7.3 | 8.4 |
| T3b, % | 2.6 | 1.6 | 3.1 | 2.8 | 4.2 | 3.1 |
| T4/N1/M1, % | 9.2 | 9.9 | 5.9 | 5.2 | 7.1 | 5.9 |
| Missing TNM stage, % | 20.3 | 18.6 | 10.5 | 12.5 | 10.1 | 9.8 |
| Gleason gradec | ||||||
| Gleason 2–6, % | 44.8 | 31.1 | 47.3 | 47.9 | 47.4 | 47.0 |
| Gleason 7, 3+4 % | 26.8 | 24.2 | 22.9 | 22.8 | 22.4 | 23.1 |
| Gleason 7, 4+3 % | 7.1 | 14.2 | 11.1 | 10.5 | 11.2 | 11.3 |
| Gleason 7 (breakdown unknown), % | 8.4 | 4.1 | 3.2 | 3.6 | 4.1 | 3.0 |
| Gleason 8–10, % | 12.9 | 26.3 | 15.5 | 15.2 | 14.8 | 15.7 |
| Missing Gleason grade, % | 26.5 | 21.2 | 15.0 | 16.8 | 15.1 | 14.3 |
MET: metabolic equivalent; PSA: prostate-specific antigen
Values are means (SD) and percentages for categorical variables are standardized to the age distribution of the study population.
a
Value is not age-adjusted
b
Combined clinical and pathologic stage (clinical stage used only if pathologic stage was unavailable)
c
Combined clinical and pathologic Gleason (clinical Gleason used only if pathologic Gleason was unavailable)